S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
S&P 500   4,538.43 (-0.84%)
DOW   34,580.08 (-0.17%)
QQQ   383.13 (-1.74%)
AAPL   161.84 (-1.17%)
MSFT   323.01 (-1.97%)
FB   306.84 (-1.14%)
GOOGL   2,840.03 (-0.67%)
AMZN   3,389.79 (-1.38%)
TSLA   1,014.97 (-6.42%)
NVDA   306.93 (-4.46%)
BABA   111.96 (-8.23%)
NIO   32.15 (-11.19%)
CGC   9.99 (-3.57%)
AMD   144.01 (-4.43%)
GE   92.77 (-2.58%)
MU   81.62 (-1.52%)
T   23.46 (+1.78%)
F   19.14 (-3.67%)
DIS   146.22 (-0.67%)
PFE   54.27 (+2.32%)
AMC   29.01 (-4.19%)
ACB   5.82 (-5.21%)
BA   198.49 (-1.92%)
NASDAQ:INCY

Incyte Stock Forecast, Price & News

$65.78
-0.85 (-1.28%)
(As of 12/3/2021 04:00 PM ET)
Add
Compare
Today's Range
$65.21
$66.79
50-Day Range
$63.34
$70.37
52-Week Range
$61.91
$101.47
Volume
2.57 million shs
Average Volume
1.43 million shs
Market Capitalization
$14.53 billion
P/E Ratio
27.29
Dividend Yield
N/A
Beta
0.76
30 days | 90 days | 365 days | Advanced Chart
Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for Incyte and its competitors with MarketBeat's FREE daily newsletter.


Incyte logo

About Incyte

Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A. Whitfield in April 1991 and is headquartered in Wilmington, DE.

Headlines

Financial Analysis: Incyte (NASDAQ:INCY) and Zymergen (NASDAQ:ZY)
November 28, 2021 |  americanbankingnews.com
Is This Pharma Stock a Buy? - Nasdaq
November 22, 2021 |  nasdaq.com
Is This Pharma Stock a Buy? - Motley Fool
November 22, 2021 |  fool.com
Incyte (NASDAQ:INCY) and Zymergen (NASDAQ:ZY) Critical Contrast
November 15, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:INCY
CUSIP
45337C10
Employees
1,773
Year Founded
1991

Sales & Book Value

Annual Sales
$2.67 billion
Book Value
$11.92 per share

Profitability

Net Income
$-295.70 million
Pretax Margin
21.23%

Debt

Price-To-Earnings

Miscellaneous

Free Float
185,990,000
Market Cap
$14.53 billion
Optionable
Optionable

Company Calendar

Last Earnings
8/03/2021
Today
12/03/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
2/08/2022

Social Links


MarketRank

Overall MarketRank

3.14 out of 5 stars

Medical Sector

19th out of 1,390 stocks

Commercial Physical Research Industry

1st out of 27 stocks

Analyst Opinion: 4.3Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 3.1 5 -4 -3 -2 -1 -












Incyte (NASDAQ:INCY) Frequently Asked Questions

Is Incyte a buy right now?

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Incyte stock.
View analyst ratings for Incyte
or view top-rated stocks.

How has Incyte's stock been impacted by COVID-19?

Incyte's stock was trading at $71.90 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, INCY stock has decreased by 8.5% and is now trading at $65.78.
View which stocks have been most impacted by COVID-19
.

When is Incyte's next earnings date?

Incyte is scheduled to release its next quarterly earnings announcement on Tuesday, February 8th 2022.
View our earnings forecast for Incyte
.

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) released its quarterly earnings results on Tuesday, August, 3rd. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.54 by $0.26. The biopharmaceutical company earned $705.71 million during the quarter, compared to analysts' expectations of $686.95 million. Incyte had a net margin of 18.35% and a trailing twelve-month return on equity of 22.27%. The company's revenue for the quarter was up 2.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.24 earnings per share.
View Incyte's earnings history
.

What price target have analysts set for INCY?

12 brokers have issued 1-year target prices for Incyte's stock. Their forecasts range from $67.00 to $109.00. On average, they anticipate Incyte's share price to reach $88.30 in the next year. This suggests a possible upside of 34.2% from the stock's current price.
View analysts' price targets for Incyte
or view top-rated stocks among Wall Street analysts.

Who are Incyte's key executives?

Incyte's management team includes the following people:
  • Herve Hoppenot, Chairman, President & Chief Executive Officer
  • Christiana Stamoulis, Chief Financial Officer & Executive Vice President
  • Steven H. Stein, Chief Medical Officer & Executive Vice President
  • Dashyant Dhanak, Chief Scientific Officer & Executive VP (LinkedIn Profile)
  • Barry Flannelly, Executive Vice President & General Manager

What is Hervé Hoppenot's approval rating as Incyte's CEO?

22 employees have rated Incyte CEO Hervé Hoppenot on Glassdoor.com. Hervé Hoppenot has an approval rating of 80% among Incyte's employees.

What other stocks do shareholders of Incyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), (MDVN) (MDVN), First Solar (FSLR), United Airlines (UAL), Dynavax Technologies (DVAX), Micron Technology (MU), (KITE) (KITE), Freeport-McMoRan (FCX) and NVIDIA (NVDA).

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Who are Incyte's major shareholders?

Incyte's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.88%), Wellington Management Group LLP (4.44%), Renaissance Technologies LLC (2.00%), Geode Capital Management LLC (1.73%), Bellevue Group AG (1.34%) and Invesco Ltd. (0.82%). Company insiders that own Incyte stock include Bros Advisors Lp Baker, Dashyant Dhanak, Herve Hoppenot, Jonathan Elliott Dickinson, Maria E Pasquale, Michael James Morrissey, Paul Trower, Paula J Swain, Steven H Stein, Vijay K Iyengar and Yao Wenqing.
View institutional ownership trends for Incyte
.

Which institutional investors are selling Incyte stock?

INCY stock was sold by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, American Century Companies Inc., Epoch Investment Partners Inc., Nippon Life Global Investors Americas Inc., SG Americas Securities LLC, NN Investment Partners Holdings N.V., Renaissance Technologies LLC, and BNP Paribas Arbitrage SA. Company insiders that have sold Incyte company stock in the last year include Dashyant Dhanak, Michael James Morrissey, Vijay K Iyengar, and Yao Wenqing.
View insider buying and selling activity for Incyte
or view top insider-selling stocks.

Which institutional investors are buying Incyte stock?

INCY stock was purchased by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, BlackRock Inc., Invesco Ltd., Man Group plc, Geode Capital Management LLC, Morgan Stanley, Grimes & Company Inc., and Jane Street Group LLC. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Herve Hoppenot.
View insider buying and selling activity for Incyte
or or view top insider-buying stocks.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $65.78.

How much money does Incyte make?

Incyte has a market capitalization of $14.53 billion and generates $2.67 billion in revenue each year. The biopharmaceutical company earns $-295.70 million in net income (profit) each year or $2.41 on an earnings per share basis.

How many employees does Incyte have?

Incyte employs 1,773 workers across the globe.

When was Incyte founded?

Incyte was founded in 1991.

What is Incyte's official website?

The official website for Incyte is www.incyte.com.

Where are Incyte's headquarters?

Incyte is headquartered at 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at (302) 498-6700, via email at [email protected], or via fax at 302-425-2750.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.